CoreCap Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

CoreCap Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-70	Closed	-$3K	–	869
2021 Q4	$3K	Buy	+70	New	+$3.17K	﹤0.01%	1861

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CoreCap Advisors's CTXR Position: Q1 2022 in Review

CoreCap Advisors sold out of Citius Pharmaceuticals (CTXR) in Q1 2022, closing a stake of 70 shares — an estimated $3K sold.

CoreCap Advisors first reported a position in CTXR in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

CoreCap Advisors reported no remaining Citius Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
CoreCap Advisors sold 70 Citius Pharmaceuticals shares in Q1 2022, an estimated $3K.
CoreCap Advisors first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 1 quarter.
CoreCap Advisors's Citius Pharmaceuticals position peaked at $3K in Q4 2021.
76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on CoreCap Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.